- Senior Investigator, Lipoprotein Metabolism Section
Alan Remaley received his B.S. in biochemistry and chemistry from the University of Pittsburgh in 1981, and a M.D. and Ph.D. in biochemistry from the University of Pittsburgh in 1987. In 1990, he completed a residency in clinical pathology at the University of Pennsylvania and became board-certified in clinical pathology in 1992. He joined the NIH in 1990 as a medical staff fellow and did a postdoctoral fellowship on lipoprotein metabolism in the Molecular Disease Branch at the NHLBI. In 1995, Dr. Remaley became a senior staff member of the Department of Laboratory Medicine at the NIH, where he is currently the Director of the Immunoassay and Special Chemistry section. In 2007, he became the Section Chief of the Lipoprotein Metabolism laboratory in the Cardiovascular and Pulmonary Branch of the NHLBI. Dr. Remaley has received numerous honors and awards over his career and is a Captain in the United States Public Health Service. He has published more than 150 peer-reviewed articles and is on the editorial board of several journals, including Journal of Lipid Research, Journal of Pediatric Biochemistry, Atherosclerosis, and Clinical Chemistry. Dr. Remaley is a member of the American Association of Clinical Chemistry (AACC), College of American Pathologists, American Heart Association, and National Lipid Association.
- (2020). Evaluation of Three Commercial Automated Assays for the Detection of Anti-SARS-CoV-2 Antibodies. CLINICAL CHEMISTRY. 66(10), 1351-1353.
- (2020). Accuracy of New Equation to Calculate Low-Density Lipoprotein Cholesterol-Reply. JAMA Cardiology.
- (2020). High-density lipoproteins are a potential therapeutic target for age-related macular degeneration. JOURNAL OF BIOLOGICAL CHEMISTRY. 295(39), 13601-13616.
- (2020). Lecithin:cholesterol acyltransferase: symposium on 50 years of biomedical research from its discovery to latest findings. JOURNAL OF LIPID RESEARCH. 61(8), 1142-1149.